CX 13 608
Alternative Names: CX-13-608Latest Information Update: 28 Jul 2021
At a glance
- Originator Ningbo Shengjian Biomedical Technology
- Class Antineoplastics; Epoxy compounds; Ketones; Peptides
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Multiple-myeloma(Refractory metastatic disease) in China (IV, Injection)
- 23 Jul 2018 Ningbo Shengjian Biomedical Technology has patent protection for CX 13 608 (WO2016011088)
- 01 Jun 2018 Phase-I clinical trials in Multiple myeloma (Refractory metastatic disease) in China (IV) (ChiCTR1800017056 )